Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ScripMandy
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ScripMandy
-
A lot of new PR pros started following me during
#JPM20. So, a reminder:@PharmaScrip &@PharmaPinkSheet only cover drugs, not medical devices or diagnostics, but our colleagues at@Medtech_Insight would love to receive your device & diagnostic news:https://medtech.pharmaintelligence.informa.com/meet-the-teamHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mandy Jackson proslijedio/la je Tweet
$BMY Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancerhttps://www.businesswire.com/news/home/20200131005545/en/Bristol-Myers-Squibb-Withdraws-European-Application-Opdivo-nivolumab …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$GILD “Gilead is working closely with global health authorities to respond to the novel coronavirus (2019-nCoV) outbreak through the appropriate experimental use of our investigational compound remdesivir.” https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus …https://twitter.com/andybiotech/status/1223310789823561728 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LLY Reyvow and$AGN Ubrelvy both have launched. Allergan confirmed that its acute#migraine drug is available in pharmacies and prescriptions are being filled.https://twitter.com/scripmandy/status/1223287214391431170 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mandy Jackson proslijedio/la je Tweet
Arcutis Biotherapeutics prices upsized IPO at $17 high end
$ARQT$IPO#IPOhttp://zpr.io/tK77mHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mandy Jackson proslijedio/la je Tweet
Oncology biotech Black Diamond Therapeutics pops 108% on IPO
$BDTX$IPO#IPOhttp://zpr.io/tKHaiHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“A benefit of ditans, like Lilly’s Reyvow, is that they are not associated with vasoconstriction, which is seen with triptans, making the older drugs contraindicated in patients with cardiovascular disease.” (Subscription required)https://scrip.pharmaintelligence.informa.com/SC141524/Market-Snapshot-Three-Acute-Migraine-Launches-Are-First-In-Over-20-Years …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LLY Reyvow list price for the on-demand migraine treatment is $640 for a package of 8 tablets (on par with $85/dose for$AGN CGRP Ubrelvy).https://scrip.pharmaintelligence.informa.com/SC141541/The-ICER-Process-Allergan-Engagement-Improves-Cost-Effectiveness-Rating-For-Ubrelvy …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LLY Is launching its acute migraine drug Reyvow (lasmiditan) now that it has received DEA scheduling - class V, the lowest potential for abuse.https://www.prnewswire.com/news-releases/lillys-reyvow-lasmiditan-c-v-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription-300996903.html …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMGN Murdo Gordon: Over 92% of commercial lives have access to migraine prevention drug Aimovig with affordable co-pay. More than 80% of prescriptions are paid. Reduction in net selling price in Q1 due to new CVS deal, but stabilizing the rest of the year.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMGN David Reese pipeline updates in line w/those in this@PharmaScrip story based on my chat w/the EVP of R&D at#JPM20 about Amgen's efforts to work more efficiently, including through use of genomics, proteomics and transcriptomics (subscription reqd).https://scrip.pharmaintelligence.informa.com/SC141559/Amgens-RD-Group-Focuses-On-Efficiency-As-Drug-Cost-Concerns-Continue …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
$AMGN Commercial EVP Murdo Gordon notes that Amgen will increase its focus on the psoriasis market now that its has two branded products in this market – Otezla and Enbrel, plus biosimilars.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMGN CFO Peter Griffith: Net 5% price decline globally in 2019, expect low to mid single-digit net price decline in 2020, which will be more than offset by increased revenue.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMGN CEO Bob Bradway continues to note, as he did at#JPM20, that Asia-Pacific will be a major source of growth. Company sees it growing to 25% of its revenue.https://twitter.com/Amgen/status/1223004613671968768 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Meanwhile,
$AMGN Q4 revenue of $6.2bn beat consensus of $6.02bn, so perhaps Amgen is aiming low and will beat its guidance significantly by the end of 2020. Beat-and-raise strategy could pay off ...Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mandy Jackson proslijedio/la je Tweet
First episode of the year for the Informa Pharma Intelligence Podcast, covering
#JPM20. Listen in as@Jessicaemerrill and@awmcconaghie share their key takeaways from the meeting:https://soundcloud.com/dmhcap/post-jpm-2020-podcast …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMGN 2020 revenue guidance of $25bn-$25.6bn aligns with analyst consensus of $25.4bn, but non-GAAP EPS guidance of $14.85-$15.60 below consensus of $16.20. Amgen's stock is down 2.7% after hours.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mandy Jackson proslijedio/la je Tweet
$AMGN#biosimilar revenues of $568m,$BIIB of $738m and$PFE of $911m in 2019; looks like biosimilars are becoming material to the top line. But for each company it is a portfolio of products and US and Europe.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mandy Jackson proslijedio/la je Tweet
Novartis AveXis President Lennon On Rebuilding Trust With FDA, Zolgensma Trial Hold, And Morehttps://pink.pharmaintelligence.informa.com/articles/2020/01/28/novartis-avexis-president-lennon-on-rebuilding-trust-with-fda-zolgensma-trial-hold-and-more …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.